Publications by authors named "Jia-Lei Weng"
Purpose: We aimed to investigate the feasibility of lenvatinib plus anti-PD-1 therapy as a conversion therapy for initially unresectable hepatocellular carcinoma (HCC).
Methods: Patients with initially unresectable HCC who received combined lenvatinib and anti-PD-1 antibody between May 2020 and Jan 2022 in Zhongshan Hospital were retrospectively analyzed. Tumor response and resectability were assessed by imaging every two months according to RECIST version 1.
Article Synopsis
- Interest in circulating cell free DNA (ccfDNA) has surged, particularly for its potential application in cancer management, as blood levels of ccfDNA correlate with various diseases.
- Unlike traditional tissue biopsies, measuring ccfDNA is a non-invasive method for cancer detection and offers benefits in monitoring disease progression and predicting patient prognosis.
- Advances in quantitative detection techniques are being developed to enhance sensitivity, addressing the challenge of ccfDNA's low concentration in blood samples.